M
Marion E. Meijer-van Gelder
Researcher at Erasmus University Rotterdam
Publications - 40
Citations - 6877
Marion E. Meijer-van Gelder is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Breast cancer & Tamoxifen. The author has an hindex of 30, co-authored 40 publications receiving 6567 citations. Previous affiliations of Marion E. Meijer-van Gelder include Erasmus University Medical Center.
Papers
More filters
Journal ArticleDOI
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.
Yixin Wang,Jan Klijn,Yi Zhang,Anieta M. Sieuwerts,Maxime P. Look,Fei Yang,Dmitri Talantov,Mieke Timmermans,Marion E. Meijer-van Gelder,Jack X. Yu,Tim Jatkoe,Els M.J.J. Berns,David Atkins,John A. Foekens +13 more
TL;DR: The ability to identify patients who have a favourable prognosis could, after independent confirmation, allow clinicians to avoid adjuvant systemic therapy or to choose less aggressive therapeutic options.
Journal ArticleDOI
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.
Maxime P. Look,Wim L. J. van Putten,Michael J. Duffy,Nadia Harbeck,Ib Jarle Christensen,Christoph Thomssen,Ronald E. Kates,Frédérique Spyratos,Mårten Fernö,Serenella Eppenberger-Castori,C. G. J. Fred Sweep,Kurt Ulm,J. P. Peyrat,Pierre-Marie Martin,Henri Magdelenat,Nils Brünner,Catherine Duggan,Björn W. Lisboa,Pär-Ola Bendahl,Véronique Quillien,A Daver,Gabriel Ricolleau,Marion E. Meijer-van Gelder,Peggy Manders,W. Edward Fiets,Marinus A. Blankenstein,Philippe Broët,Sylvie Romain,Günter Daxenbichler,Gudrun Windbichler,Tanja Cufer,Simona Borštnar,Willy Kueng,Louk V.A.M. Beex,Jan G. M. Klijn,Niall O'Higgins,Urs Eppenberger,Fritz Jänicke,Manfred Schmitt,John A. Foekens +39 more
TL;DR: For patients with lymph node-negative breast cancer, uPA and PAI-1 measurements in primary tumors may be especially useful for designing individualized treatment strategies.
Journal ArticleDOI
Molecular Classification of Tamoxifen-Resistant Breast Carcinomas by Gene Expression Profiling
Maurice P.H.M. Jansen,John A. Foekens,Iris L. van Staveren,Maaike J.M. Dirkzwager-Kiel,Kirsten Ritstier,Maxime P. Look,Marion E. Meijer-van Gelder,Anieta M. Sieuwerts,H. Portengen,Lambert C. J. Dorssers,Jan G. M. Klijn,Els M.J.J. Berns +11 more
TL;DR: Data show that gene expression profiling can be used to discriminate between breast cancer patients with progressive disease and objective response to tamoxifen, and additional studies are needed to confirm if the predictive signature might allow identification of individual patients who could benefit from other endocrine therapies.
Journal Article
RNA Expression of Breast Cancer Resistance Protein, Lung Resistance-related Protein, Multidrug Resistance-associated Proteins 1 and 2, and Multidrug Resistance Gene 1 in Breast Cancer: Correlation with Chemotherapeutic Response
Herman Burger,John A. Foekens,Maxime P. Look,Marion E. Meijer-van Gelder,Jan G. M. Klijn,Erik A.C. Wiemer,Gerrit Stoter,Kees Nooter +7 more
TL;DR: MDR1 expression in primary breast tumors was inversely related with the efficacy of first-line chemotherapy, and high expression level was a significant predictor of poor prognosis for patients with advanced disease.
Journal Article
Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
Nadia Harbeck,Ronald E. Kates,Maxime P. Look,Marion E. Meijer-van Gelder,Jan G. M. Klijn,Achim Krüger,Marion Kiechle,Fritz Jänicke,Manfred Schmitt,John A. Foekens +9 more
TL;DR: UPA and PAI-1 levels in primary tumor tissue provide clinically relevant information on relapse risk and treatment response that will help to tailor adjuvant therapy concepts in breast cancer, accounting for individual biological tumor characteristics.